company background image
ELTP logo

Elite Pharmaceuticals OTCPK:ELTP Stock Report

Last Price

US$0.20

Market Cap

US$210.9m

7D

11.3%

1Y

436.3%

Updated

19 Jul, 2024

Data

Company Financials

Elite Pharmaceuticals, Inc.

OTCPK:ELTP Stock Report

Market Cap: US$210.9m

ELTP Stock Overview

A specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals.

ELTP fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health5/6
Dividends0/6

Elite Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Elite Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.20
52 Week HighUS$0.21
52 Week LowUS$0.036
Beta0.099
11 Month Change18.44%
3 Month Change53.06%
1 Year Change436.33%
33 Year Change327.91%
5 Year Change290.16%
Change since IPO-90.05%

Recent News & Updates

Recent updates

Shareholder Returns

ELTPUS PharmaceuticalsUS Market
7D11.3%-3.4%-0.7%
1Y436.3%18.3%20.2%

Return vs Industry: ELTP exceeded the US Pharmaceuticals industry which returned 18.3% over the past year.

Return vs Market: ELTP exceeded the US Market which returned 20.2% over the past year.

Price Volatility

Is ELTP's price volatile compared to industry and market?
ELTP volatility
ELTP Average Weekly Movement8.6%
Pharmaceuticals Industry Average Movement10.0%
Market Average Movement5.9%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: ELTP's share price has been volatile over the past 3 months.

Volatility Over Time: ELTP's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199764Nasrat Hakimwww.elitepharma.com

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases.

Elite Pharmaceuticals, Inc. Fundamentals Summary

How do Elite Pharmaceuticals's earnings and revenue compare to its market cap?
ELTP fundamental statistics
Market capUS$210.88m
Earnings (TTM)US$20.11m
Revenue (TTM)US$56.63m

10.6x

P/E Ratio

3.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ELTP income statement (TTM)
RevenueUS$56.63m
Cost of RevenueUS$30.27m
Gross ProfitUS$26.36m
Other ExpensesUS$6.25m
EarningsUS$20.11m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.019
Gross Margin46.55%
Net Profit Margin35.51%
Debt/Equity Ratio13.2%

How did ELTP perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.